Li, Jin
Bai, Yuxian
Chen, Zhendong
Ying, Jieer
Guo, Yabing
Fang, Weijia
Zhang, Feng
Xiong, Jianping
Zhang, Tao
Meng, Zhiqiang
Zhang, Jingdong
Ren, Zhenggang
Hao, Chunyi
Chen, Yajin
Lin, Xiaoyan
Pan, Hongming
Zhou, Fuxiang
Li, Xin
Yu, Fan
Zhang, Juan
Zhang, Zhang
Qin, Shukui
Funding for this research was provided by:
BeiGene, Ltd
Article History
Received: 29 April 2024
Accepted: 8 August 2024
First Online: 5 September 2024
Declarations
:
: Jin Li reports payments or honoraria for consulting or speakers bureaus from ArteMed Hospital, Novartis, HengRui, BI, and Lilly; Jieer Ying and Hongming Pan report stocks or shares in BeiGene (institutional relationship with financial interest); Zhenggang Ren reports a consulting or advisory role with AstraZeneca, Roche, and Merck Sharp & Dohme; Zhang Zhang and Juan Zhang report financial relationships with BeiGene; Xin Li and Fan Yu report full-time employment by BeiGene; Yuxian Bai, Zhendong Chen, Yabing Guo, Weijia Fang, Feng Zhang, Jianping Xiong, Tao Zhang, Zhiqiang Meng, Jingdong Zhang, Chunyi Hao, Yajin Chen, Xiaoyan Lin, Fuxiang Zhou, and Shukui Qin have no potential conflict of interest to report.
: This study was performed in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and the principles of informed consent. Written informed consent was obtained from each patient prior to screening. The protocol was approved by an independent ethics committee prior to initiation.
: Not applicable.
: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.